CORDIS
Wyniki badań wspieranych przez UE

CORDIS

Polski PL

Site-selective protein-modification chemistries for antibody-drug conjugates (ADCs)

Cel

SIMICA will provide IMM with the opportunity to integrate the European circle of research excellence institutions by cementing a sustainable science, technology and innovation network with internationally-leading organisations in the field of protein drug-conjugates. The strategy of SIMICA is based on science- and innovation-driven clustering, and is focused on the exciting and upcoming area of designing and constructing the next generation of chemically-defined and innovative protein drug-conjugates for the targeted treatment of serious conditions such as cancer. The project will allow: i) strengthening the science and technology capacity of IMM and ii) leverage its research excellence and value creation through innovation with a beneficial and quantifiable impact for the entire research and development community at IMM, the Lisbon region and Portugal. The successful implementation of this strategy will rely on specific actions, including: 1) cementing of existing and the creation of new scientific, innovative and technical collaborations through short-term staff exchanges and short-term on-site training activities; 2) training, mentoring and international exposure of IMM’s young researchers and students; 3) building an innovation ecosystem centred at IMM; 4) igniting the entrepreneurial spirit among IMM’s research community; 5) increasing science awareness among the general public through targeted dissemination and communication activities; and 6) developing a sustainability strategy to sustain the cemented network beyond project terminus. Through the completion of these activities, IMM, supported by its twinning partners, is in the best temporal and spatial position to achieve an improved capability to compete for internationally competitive research funding and to access business stakeholders. By claiming its position in research and innovation networks IMM will effectively contribute to research excellence and value creation in health at European level.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordynator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Adres

Avenida Prof Egas Moniz
1649 028 Lisboa

Portugalia

Rodzaj działalności

Research Organisations

Wkład UE

€ 350 000

Uczestnicy (4)

Sortuj alfabetycznie

Sortuj według wkładu UE

Rozwiń wszystko

ALLCYTE GMBH

Austria

Wkład UE

€ 60 000

ACADEMISCH ZIEKENHUIS LEIDEN

Niderlandy

Wkład UE

€ 35 000

PERCUROS BV

Niderlandy

Wkład UE

€ 165 000

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Zjednoczone Królestwo

Wkład UE

€ 190 000

Informacje na temat projektu

Identyfikator umowy o grant: 852985

Status

Projekt w realizacji

  • Data rozpoczęcia

    1 Października 2019

  • Data zakończenia

    30 Września 2022

Finansowanie w ramach:

H2020-EU.4.b.

  • Całkowity budżet:

    € 800 000

  • Wkład UE

    € 800 000

Koordynowany przez:

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugalia